Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Sees Large Decline in Short Interest

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) saw a significant decline in short interest in the month of September. As of September 30th, there was short interest totalling 3,400 shares, a decline of 35.8% from the September 15th total of 5,300 shares. Approximately 0.0% of the company's shares are sold short. Based on an average trading volume of 8,100 shares, the days-to-cover ratio is currently 0.4 days.

Armata Pharmaceuticals Trading Up 0.9 %

Shares of Armata Pharmaceuticals stock traded up $0.02 during trading on Friday, hitting $2.37. 9,814 shares of the stock traded hands, compared to its average volume of 12,866. Armata Pharmaceuticals has a 52-week low of $1.90 and a 52-week high of $4.48. The firm has a market cap of $85.75 million, a P/E ratio of -1.01 and a beta of 0.80.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP - Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.52) by ($0.13). Analysts forecast that Armata Pharmaceuticals will post -1.02 earnings per share for the current year.

Institutional Trading of Armata Pharmaceuticals

A hedge fund recently raised its stake in Armata Pharmaceuticals stock. SeaCrest Wealth Management LLC increased its stake in shares of Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Free Report) by 80.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,777 shares of the company's stock after purchasing an additional 14,647 shares during the period. SeaCrest Wealth Management LLC owned 0.09% of Armata Pharmaceuticals worth $137,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 3.57% of the company's stock.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a "buy" rating and set a $7.00 target price on shares of Armata Pharmaceuticals in a research report on Thursday, August 15th.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.